Annual Surveillance Summary: Vancomycin-Resistant Enterococci (VRE) Infections in the Military Health System (MHS), 2015
Abstract
This report provides an annual update for calendar year 2015 of vancomycin-resistant Enterococci (VRE) infection burden among Military Health System (MHS) beneficiaries from previously reported retrospective data. The methods assess the demographics, clinical characteristics, prescription practices, and antibiotic susceptibility patterns for VRE infections across the Department of Defense (DOD) and Department of the Navy (DON) active duty (AD) service members with deployment-related infections. In 2015, the annual VRE incidence rate (IR) for all MHS beneficiaries was 1.60 per 100,000 persons per year, reflecting a 19.4 increase compared to the weighted historic IR. United States West and South regions accounted for the highest IRs, and healthcare-associated cases were the largest proportion of all infections identified. A substantial percentage of HA cases were classified as community-onset and multi-drug resistant organism admission metrics demonstrated a higher magnitude of VRE was imported into the MHS. This indicates a need to evaluate the potential for community transmission of VRE. Treatment for VRE infections among DOD beneficiaries primarily included daptomycin and linezolid, which remained effective throughout 2015.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2017
- Accession Number
- AD1032753
Entities
People
- Kristen Rossi
- Uzo Chukwuma
Organizations
- Navy and Marine Corps Public Health Center